BioSpace News Archive

STERIS Declares $0.43 per share Dividend - May 04, 2022

STERIS plc announced that the Company will distribute a quarterly interim dividend of $0.43 per share.

May 4, 2022
·
6 min read
Business

Quidel Reports First Quarter 2022 Financial Results

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2022.

May 4, 2022
·
16 min read
Biotech Bay

Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”

Atreca, Inc. announced the peer-reviewed publication of preclinical data demonstrating how its lead product candidate, ATRC-101, activates the immune system and drives tumor destruction in a Proceedings of the National Academy of Sciences paper.

May 4, 2022
·
5 min read
BioCapital

Danaher To Present At Bank Of America Securities Health Care Conference

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 11, 2022 at 10:00 a.m. PT.

May 4, 2022
·
1 min read
Business

NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022

NANOBIOTIX announced that it will report its financial results for the first quarter of 2022 ending March 31, 2022, on Wednesday, May 18, 2022, after the close of the US market.

May 4, 2022
·
7 min read
Drug Development

First Patient Dosed in Phase II Renal Cancer Theranostics Study

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in the ‘STARLITE 2' Phase II study of the Company’s investigational renal cancer therapy, TLX250 (177Lu-DOTA-girentuximab), at Memorial Sloan Kettering Cancer Center (MSK) in New York.

May 4, 2022
·
5 min read
Bio NC

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 04, 2022

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 23 newly-hired employees stock options to purchase an aggregate of 138,100 shares, and restricted stock units covering an aggregate of 69,050 shares, of BioCryst common stock.

May 4, 2022
·
1 min read
Business

Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2022.

May 4, 2022
·
9 min read
Business

DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2022 Financial Results

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update and released financial results for the quarter ended March 31, 2022.

May 4, 2022
·
13 min read
Business

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

Cognition Therapeutics, Inc. announced that it will report financial results for the first quarter ended March 31, 2022 in the form of a press release before the financial markets open on Wednesday, May 11, 2022.

May 4, 2022
·
4 min read